In our last episode, we explored the manufacturing strategies that will be key to scaling advanced therapies. Now, we turn our focus to the UK, where new regulatory frameworks and regional collaboration are changing how therapies reach patients.
Stuart speaks with Jacqueline Barry, Chief Clinical Officer at the Cell and Gene Therapy Catapult, about the evolution of regulation, the role of the MHRA, and why decentralised manufacturing could unlock faster, more flexible access to treatments. Then, Sarah Albon, Director of the Cambridge Cellular Therapy Laboratory, joins to share how Cambridge is preparing to become a regional hub for manufacturing, and what this shift could mean for patients across the East of England and beyond.
Together, they reveal how regulation, clinical insight, and patient needs are converging to shape the next chapter of cell and gene therapy in the UK.
Guests:
- Jacqueline Barry, Chief Clinical Officer, Cell and Gene Therapy Catapult
- Sarah Albon, Director, Cambridge Cellular Therapy Laboratory at Cambridge University Hospitals NHS Foundation Trust
